Octapharma
Clinical trials sponsored by Octapharma, explained in plain language.
-
Immune therapy tested for Kids' Sudden-Onset OCD
Disease control CompletedThis Phase 3 trial tested whether an immune therapy called Panzyga (IVIG) could reduce severe obsessive-compulsive and behavioral symptoms in children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS). The study involved 71 children and teenagers, comparing Panzy…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for tots with rare bleeding disorder
Disease control CompletedThis study tested a drug called Wilate to see if it could safely prevent bleeding episodes in very young children with a severe form of von Willebrand disease (VWD), a rare bleeding disorder. Twelve children under 6 years old received regular doses of Wilate for a year to see how…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Can antibody infusions shield cancer patients from dangerous infections?
Prevention CompletedThis study tested whether regular infusions of Panzyga (an antibody product) could prevent serious infections in adults with chronic lymphocytic leukemia (CLL) who have low antibody levels. 247 participants were randomly assigned to receive either Panzyga or a placebo infusion ev…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Prevention
Last updated Apr 01, 2026 14:43 UTC